137 related articles for article (PubMed ID: 15535307)
21. Medical treatment of epithelial ovarian cancer.
González-Martín AJ
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503.
Matsumoto K; Katsumata N; Saito I; Shibata T; Konishi I; Fukuda H; Kamura T
Jpn J Clin Oncol; 2012 Mar; 42(3):222-5. PubMed ID: 22323553
[TBL] [Abstract][Full Text] [Related]
23. Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
Nishio S; Sugiyama T; Shouji T; Yoshizaki A; Kitagawa R; Ushijima K; Kamura T
Gynecol Oncol; 2007 Aug; 106(2):342-7. PubMed ID: 17499346
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel in the management of ovarian cancer.
Blagden SP; Kaye SB
Expert Rev Anticancer Ther; 2005 Apr; 5(2):203-14. PubMed ID: 15877518
[TBL] [Abstract][Full Text] [Related]
25. [New drugs for unresectable or recurrent gastric cancer--paclitaxel and docetaxel].
Yoshida M; Ohtsu A
Nihon Rinsho; 2001 Apr; 59 Suppl 4():404-8. PubMed ID: 11424415
[No Abstract] [Full Text] [Related]
26. [Treatment of recurrent ovarian cancer].
Kudo R; Sagae S
Gan To Kagaku Ryoho; 1992 Oct; 19(12):1991-7. PubMed ID: 1358032
[TBL] [Abstract][Full Text] [Related]
27. Treatment for recurrent ovarian cancer. A report of 2 cases.
Maxwell AM; Jordaan JP
S Afr Med J; 1987 Feb; 71(3):180. PubMed ID: 3810370
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
Goldberg JM; Piver MS; Hempling RE; Recio FO
Gynecol Oncol; 1996 Dec; 63(3):312-7. PubMed ID: 8946864
[TBL] [Abstract][Full Text] [Related]
29. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
30. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy and toxicity of a taxotere/cisplatin combination in first line chemotherapy in patients with disseminated ovarian cancer].
Gorbunova VA; Khokhlova SV; Besova NS; Orel NF; Kuznetsov VV; Bliumenberg AG; Smirnova NB; Chekalova MA; Sinitsyna ME; Poddubnyĭ BK
Vopr Onkol; 2001; 47(5):1-6. PubMed ID: 11799946
[No Abstract] [Full Text] [Related]
32. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
33. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
Crotzer DR; Sun CC; Coleman RL; Wolf JK; Levenback CF; Gershenson DM
Gynecol Oncol; 2007 May; 105(2):404-8. PubMed ID: 17292461
[TBL] [Abstract][Full Text] [Related]
34. [Paclitaxel/carboplatin in first line treatment of advanced ovarian carcinoma].
Meerpohl HG
Praxis (Bern 1994); 1999 Mar; 88(12):513-8. PubMed ID: 10235026
[TBL] [Abstract][Full Text] [Related]
35. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
36. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
37. [Chemotherapy for ovarian cancer--introduction].
Yamada H; Sugiyama T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():540-5. PubMed ID: 15535304
[No Abstract] [Full Text] [Related]
38. [Chemotherapy for recurrent ovarian cancer].
Nishimura H; Imamura K; Chang C
Gan To Kagaku Ryoho; 1996 Aug; 23(9):1124-8. PubMed ID: 8751798
[TBL] [Abstract][Full Text] [Related]
39. Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.
Ozols RF
J Clin Oncol; 1997 Jun; 15(6):2177-80. PubMed ID: 9196128
[No Abstract] [Full Text] [Related]
40. Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer.
Hwang JH; Yoo HJ; Lim MC; Seo SS; Park SY; Kang S
Anticancer Drugs; 2012 Mar; 23(3):321-5. PubMed ID: 22156765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]